Check for updates

OPEN ACCESS

EDITED BY Francisco Tustumi, University of São Paulo, Brazil

REVIEWED BY Mohsen Norouzinia, Shahid Beheshti University of Medical Sciences, Iran Naseem Akhtar Qureshi, Al-Falah University, India

*CORRESPONDENCE Guohua Chen ⊠ cghys_2008@163.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 14 November 2023 ACCEPTED 27 May 2024 PUBLISHED 22 July 2024

CITATION

Du Y, Wang R, Xu X, Wang J, Shao W and Chen G (2024) Causality between major depressive disorder and functional dyspepsia: a two-sample Mendelian randomization study. *Front. Neurol.* 15:1338153. doi: 10.3389/fneur.2024.1338153

COPYRIGHT

© 2024 Du, Wang, Xu, Wang, Shao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Causality between major depressive disorder and functional dyspepsia: a two-sample Mendelian randomization study

Yaming Du^{1†}, Rui Wang^{2,3†}, Xinzi Xu¹, Junli Wang⁴, Wei Shao⁴ and Guohua Chen^{1,4}*

¹Clinical College of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan City, China, ²Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, ³Center for General Practice Medicine, Department of Integrated Traditional Chinese and Western Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China, ⁴Department of Neurology, Wuhan No. 1 Hospital, Wuhan City, China

Background: To investigate the causal relationship between major depression and functional dyspepsia using two-sample Mendelian randomization.

Methods: Data for major depression and functional dyspepsia were obtained from genome-wide association studies. We selected Single Nucleotide Polymorphisms (SNPs) strongly associated with severe depression. Mendelian randomization analysis was conducted using methods such as Inverse-Variance Weighted (IVW), MR-Egger, and Weighted Median Estimator (WME). Sensitivity analysis was performed to assess the robustness of the results.

Results: A total of 31 eligible SNPs were identified as instrumental variables for major depression. IVW analysis indicated a positive causal relationship between the two conditions ($\beta = 0.328$; SE = 0.137; p = 0.017), suggesting that severe depression increases the risk of functional dyspepsia (OR = 1.389; 95% CI: 1.062–1.816). Sensitivity tests showed no evidence of heterogeneity or horizontal pleiotropy (p > 0.05).

Conclusion: MR analysis had shown that major depressive disorder is associated with an increased risk of functional dyspepsia.

KEYWORDS

Mendelian randomization, major depressive disorder, functional dyspepsia, causal relationship, disease risk

1 Introduction

Functional dyspepsia (FD) is a clinically common gastrointestinal disorder originating from the stomach and duodenum, accounting for approximately 80% of all cases of indigestion. Its primary symptoms include epigastric pain or burning, early satiety during meals, and postprandial fullness. Importantly, these symptoms occur in the absence of any evidence of organic disease that could explain the discomfort (1, 2). FD is a complex, multifactorial disorder associated with gastrointestinal sensory and motor dysfunction, immune dysregulation, and changes in gut microbiota. Studies indicate that 10–30% of the population is affected by FD (3). Risk factors for the onset of FD include being female, smoking,

Helicobacter pylori infection, acute gastrointestinal inflammation, the use of non-steroidal anti-inflammatory drugs, and mental disorders (4).

Major depressive disorder (MDD) is closely associated with FD (Functional dyspepsia), often co-occurring, but their causal relationship remains unconfirmed. Mendelian randomization (MR) is an epidemiological analysis method that employs genetic variations strongly correlated with exposure or risk factors as instrumental variables (IV) to assess whether there is a causal relationship between exposure or risk factors and clinically relevant outcomes (5). Single nucleotide polymorphisms (SNPs) are the most commonly used genetic variations in MR studies. Because the alleles related to exposure are randomly assigned and are generally unaffected by environmental factors acquired later in life (6), MR analysis not only shares the benefits of randomized allocation in randomized controlled trials (7), but is also less susceptible to biases such as confounding or reverse causality (8). Therefore, the current study aims to investigate the causal relationship between MDD and FD through a two-sample MR analysis.

2 Materials and methods

2.1 Study design

Valid instrumental variables (IVs) are crucial for MR (Mendelian Randomization) studies and must adhere to the three core assumptions of MR analysis (6, 8): ① Relevance assumption: the IVs must be strongly correlated with the exposure variable (MDD); ② Independence assumption: the IVs should not be related to any confounders; ③ Exclusion restriction assumption: the IVs must influence the outcome (FD) only through the exposure variable (MDD), and not through any other pathways. See Figure 1.

2.2 Data source

The genome-wide association study (GWAS) data for both the exposure (MDD) and the outcome (FD) used in this study were sourced from the website https://gwas.mrcieu.ac.uk/datasets/. The data for MDD was obtained from the Psychiatric Genomics Consortium (PGC) and is based on a 2018 GWAS summary that includes 480,359 participants (135,458 cases and 344,901 controls).



The FD data comes from a 2021 GWAS summary and includes a sample size of 194,071, consisting of 4,376 cases and 189,695 controls. Both the MDD and FD samples were of European ancestry. Detailed information can be found in Table 1.

2.3 Selection of instrumental variables

In this study, suitable SNPs will be selected as instrumental variables (IVs) by adhering to the three core assumptions of MR. First, SNPs with genome-wide significance ($p < 5 \times 10^{-8}$) will be filtered from the GWAS data for MDD. To control for the impact of linkage disequilibrium (LD), parameters are set at $r^2 < 0.001$ and a distance of 10,000 kb. PhenoScanner database will be utilized to search the phenotypes of each SNP to rule out the effects of confounding factors (9). To ensure that the selected SNPs are strongly correlated with the exposure, the *F*-statistic will be employed to evaluate the weak instrument effect. An *F*-value greater than 10 will be considered indicative of no weak instrument bias (10).

2.4 MR analysis

This study will conduct two-sample MR analysis using the TwoSampleMR package in R version 4.3.1. The primary analytical methods include inverse-variance weighted (IVW), MR-Egger regression, and weighted median estimator (WME) (11). IVW provides accurate causal estimates under the assumption that all variants are valid instrumental variables (12).

2.5 Sensitivity analysis

To evaluate the robustness of the conclusions, sensitivity analyses will be performed on the results, which include heterogeneity tests, horizontal pleiotropy tests, and Leave-One-Out analysis. (1) Heterogeneity Tests (13): Cochran's Q test will be used to examine heterogeneity across instrumental variables, to evaluate differences among different SNPs (p > 0.05 indicates no heterogeneity). (2) Horizontal Pleiotropy Tests: MR-Egger intercept (13) (when the intercept term in MR-Egger is close to zero, it suggests no horizontal pleiotropy among SNPs; if it diverges significantly from zero, it suggests the presence of horizontal pleiotropy) and MR-PRESSO (14) (Global test p > 0.05, indicating no horizontal pleiotropy) will be used to test for horizontal pleiotropy. (3) Leave-One-Out Analysis: each SNP will be sequentially removed to observe whether the results change upon omission. If the removal of SNPs one by one does not significantly impact the results, this suggests the analysis is robust. All statistical tests with p < 0.05 are considered statistically significant.

3 Results

3.1 Instrumental variables associated with MDD

After screening with the criteria of $p < 5 \times 10^{-8}$ and removing linkage disequilibrium (LD), an initial set of 36 SNPs was obtained.



Disease	Sample size	Population	Number of SNPs	Gender	Publication year
MDD	480,359	European	10,000	Mixed Gender	2018
FD	194,071	European	16,380,380	Mixed Gender	2021



Confounders were eliminated through the PhenoScanner database, and the remaining SNPs were matched with the outcome dataset and palindromic sequences were removed, resulting in 31 SNPs being selected as instrumental variables for MDD. Calculation shows that the *F*-values of all included SNPs are consistently greater than 10, suggesting that the influence of weak instrumental variables is unlikely.

3.2 MR analysis results

The IVW analysis indicates a positive causal relationship between MDD and FD (β =0.328; SE=0.137; p=0.017). MDD is associated with an increased risk of FD (OR=1.389; 95% CI: 1.062–1.816), as shown in Figures 2, 3.

3.3 Sensitivity analysis

The Q-tests for both IVW (p=0.391) and MR-Egger regression (p=0.351) show no heterogeneity among the included SNPs, as depicted in Figure 4. The MR-Egger intercept is close to zero

(MR-Egger intercept = -0.008, p = 0.679), and the MR-PRESSO Global Test p = 0.484 > 0.05, indicating the absence of horizontal pleiotropy. The Leave-one-out method did not identify any SNPs that significantly influenced the estimates, suggesting that the analysis results are robust, as depicted in Figure 5.

4 Discussion

Major Depressive Disorder (MDD) is a prevalent and severe mental illness that increases the risk of various somatic diseases. Past cohort studies and meta-analyses have indicated a correlation between depressive symptoms and Functional Dyspepsia (FD). A matched cohort study based on 40,394 participants showed that depression is associated with an increased risk of developing FD, with an adjusted HR of 2.16 and a 95% CI of 1.93 to 2.41 (15). Another meta-analysis that included 23 studies also demonstrated a significant association between FD and depression (16). However, the evidence for this relationship remains inconclusive due to confounding factors and reverse causality often found in observational studies. This study identifies a link between MDD and FD using two-sample Mendelian







Randomization (MR) methods, establishing MDD as a risk factor for FD.

The relationship between Major Depressive Disorder (MDD) and gastrointestinal diseases is distinct from other chronic conditions, due to the unique interaction between the central nervous system and the gastrointestinal tract, also known as the brain-gut axis. The interplay between MDD and Functional Dyspepsia (FD) is complex, involving physiological, neuroendocrine, immunological, and gut microbiota factors. Key aspects include: 1 Dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis: research indicates that HPA axis dysfunction is observed in patients with psychiatric disorders and mood disorders. In patients with MDD, abnormalities in the HPA axis manifest as increased secretion and reactivity of cortisol, along with elevated levels of corticotropin-releasing hormone (CRH) in cerebrospinal fluid (17). Activation of CRH receptors can interact with various CRF receptor subtypes, leading to inhibited gastric emptying and altered colonic motility (18). Furthermore, cortisol receptors are expressed in various intestinal cells, indicating that cortisol has a direct impact on the gastrointestinal tract (19). 2 Alterations in Gut Microbiota: studies have shown a link between MDD and changes in gut microbial abundance (20). Research by

Jiang et al. found a reduction in Faecalibacterium in MDD patients, which negatively correlated with the severity of depressive symptoms (21). ③ Inflammatory Response: research has indicated that MDD is associated with systemic immune activation, leading to increased levels of pro-inflammatory cytokines (22). These elevated cytokines may compromise the intestinal mucosal barrier, contributing to the pathogenesis of FD. In addition, MDD can also cause gastrointestinal symptoms by affecting substances like brain-gut peptides and serotonin.

This study is the first to definitively establish the relationship between Major Depressive Disorder (MDD) and Functional Dyspepsia (FD) using Mendelian Randomization (MR) methods. The SNPs used in the study showed strong correlation with MDD ($p < 5 \times 10^{-8}$, F > 10) and were pruned for linkage disequilibrium with the condition $r^2 < 0.001$, kb = 10,000 to ensure their independence. In terms of results, the Inverse Variance Weighted (IVW) method showed significant results, while MR-Egger and the Weighted Median Estimator (WME) methods did not. However, no pleiotropy or heterogeneity was observed, and the beta values obtained from other methods were consistent in direction with the IVW method. Thus, we can infer a positive causal relationship between MDD and FD. Nevertheless, this study has some limitations. The population included was of European descent, so the conclusions may not be generalizable to other ethnic groups and further studies are required to explore this. Moreover, since the samples in this study came from the public database, exposure variables could not be stratified according to gender or age, so the effect of age or sex on this causal relationship cannot be determined.

In summary, this study used a two-sample MR analysis method to assess whether MDD has an impact on the onset of FD. Genetic evidence suggests that individuals with MDD are at an increased risk of developing FD, identifying it as a genetic risk factor for the onset of FD. This offers clinical insights, as many depressive patients present with gastrointestinal discomfort as their primary symptom upon consultation, often masking the underlying etiology and leading to misdiagnoses, resulting in suboptimal treatment outcomes. Concurrently, when addressing the pathogenesis of FD, one should fully consider the neuropsychological status of the patient.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found at: Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) OpenGWAS project, https://gwas.mrcieu. ac.uk/datasets/.

Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the patients/participants or patients/participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Author contributions

YD: Writing – original draft, Writing – review & editing. RW: Data curation, Writing – original draft, Writing – review & editing.

References

1. Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, et al. British Society of gastroenterology guidelines on the management of functional dyspepsia. *Gut.* (2022) 71:1697–723. doi: 10.1136/gutjnl-2022-327737

2. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. (2020) 396:1689-702. doi: 10.1016/S0140-6736(20)30469-4

3. Sayuk GS, Gyawali CP. Functional dyspepsia: diagnostic and therapeutic approaches. *Drugs.* (2020) 80:1319–36. doi: 10.1007/s40265-020-01362-4

4. Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, et al. United European gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. *United European Gastroenterol J*. (2021) 9:307–31. doi: 10.1002/ueg2.12061

5. Wade KH, Yarmolinsky J, Giovannucci E, Lewis SJ, Millwood IY, Munafò MR, et al. Applying Mendelian randomization to appraise causality in relationships between nutrition and cancer. *Cancer Causes Control.* (2022) 33:631–52. doi: 10.1007/ s10552-022-01562-1

6. Li J, Li C, Huang Y, Guan P, Huang D, Yu H, et al. Mendelian randomization analyses in ocular disease: a powerful approach to causal inference with human genetic data. *J Transl Med.* (2022) 20:621. doi: 10.1186/s12967-022-03822-9

XX: Data curation, Methodology, Writing – review & editing. JW: Writing – review & editing. WS: Supervision, Writing – review & editing. GC: Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was funded by the Second Leading Medical Talents Project of Hubei Province.

Acknowledgments

We acknowledge the GWAS database for providing the data and all the researchers involved in the original study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1338153/ full#supplementary-material

7. Ference BA, Holmes MV, Smith GD. Using Mendelian randomization to improve the design of randomized trials. *Cold Spring Harb Perspect Med.* (2021) 11:40980. doi: 10.1101/cshperspect.a040980

8. Gupta V, Walia GK, Sachdeva MP. Mendelian randomization: an approach for exploring causal relations in epidemiology. *Public Health.* (2017) 145:113–9. doi: 10.1016/j.puhe.2016.12.033

9. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinform*. (2019) 35:4851–3. doi: 10.1093/bioinformatics/btz469

10. Andrews SJ, Goate A, Anstey KJ. Association between alcohol consumption and Alzheimer's disease: a Mendelian randomization study. *Alzheimers Dement*. (2020) 16:345–53. doi: 10.1016/j.jalz.2019.09.086

11. Broadbent JR, Foley CN, Grant AJ, Mason AM, Staley JR, Burgess S. Mendelian randomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. *Wellcome Open Res.* (2020) 5:252. doi: 10.12688/ wellcomeopenres.16374.2

12. Zagkos L, Dib MJ, Pinto R, Gill D, Koskeridis F, Drenos F, et al. Associations of genetically predicted fatty acid levels across the phenome: a Mendelian randomization study. *PLoS Med.* (2022) 19:e1004141. doi: 10.1371/journal.pmed.1004141

13. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. *Res Synth Methods.* (2019) 10:486–96. doi: 10.1002/jrsm.1346

14. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* (2018) 50:693–8. doi: 10.1038/s41588-018-0099-7

15. Kao KL, Sung FC, Huang HC, Lin CJ, Chen SC, Lin CL, et al. Functional dyspepsia in depression: a population-based cohort study. *Eur J Clin Investig.* (2021) 51:e13506. doi: 10.1111/eci.13506

16. Lin S, Gao T, Sun C, Jia M, Liu C, Ma A. The association between functional dyspepsia and depression: a meta-analysis of observational studies. *Eur J Gastroenterol Hepatol.* (2019) 31:911–8. doi: 10.1097/MEG.000000000001451

17. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. *Prog Neuro-Psychopharmacol Biol Psychiatry*. (2011) 35:722–9. doi: 10.1016/j.pnpbp.2010.04.011

18. Lv Y, Wen J, Fang Y, Zhang H, Zhang J. Corticotropin-releasing factor receptor 1 (CRF-R1) antagonists: promising agents to prevent visceral hypersensitivity in irritable bowel syndrome. *Peptides*. (2022) 147:170705. doi: 10.1016/j.peptides.2021.170705

19. Rusch JA, Layden BT, Dugas LR. Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. *Front Endocrinol.* (2023) 14:1130689. doi: 10.3389/ fendo.2023.1130689

20. Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. *Front Psych.* (2019) 10:34. doi: 10.3389/fpsyt.2019.00034

21. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun.* (2015) 48:186–94. doi: 10.1016/j.bbi.2015.03.016

22. Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. *Neuron*. (2020) 107:234–56. doi: 10.1016/j. neuron.2020.06.002